Since tumor cells are more susceptible to TRAIL-induced cell death compared to healthy cells, and TRAIL can selectively target tumor-associated feeder cells, TRAIL has been the center of cancer therapy studies (22, 24, 45–48, 164). The gene discussed is TNFSF10; the disease is neoplasm.